Please provide your email address to receive an email when new articles are posted on . Moderate exacerbations shared similar characteristics with severe exacerbations. Lung function, limitations and ...

Compared with placebo, the time to first moderate or severe exacerbation was longer with mepolizumab. HealthDay News — For patients with chronic obstructive pulmonary disease (COPD) with a history of ...

NICE has recommended dupilumab for adults with uncontrolled COPD and raised eosinophils, citing fewer exacerbations and ...

All dose groups demonstrated good safety and tolerability versus placebo, with similar adverse event (AE) incidence (70% vs. 85%). At the recommended Phase IIb dose (RP2D), the annualized rate of ...

Please provide your email address to receive an email when new articles are posted on . Patients receiving dupilumab vs. placebo had a significantly lower risk for at least one severe exacerbation.

DPP-1 inhibitors and macrolides likely reduce the frequency of exacerbations in patients with non-cystic fibrosis bronchiectasis compared with placebo, a network meta-analysis shows.

High-intensity noninvasive positive pressure ventilation (NPPV) might have reduced need for endotracheal intubation for persistent hypercapnia during acute exacerbation of chronic obstructive ...

Omalizumab or dupilumab suggested for adults with moderate-to-severe allergic asthma, history of exacerbations requiring oral corticosteroids ...

Imaging and clinical characteristics reach high diagnostic efficacy when they are used to identify frequent acute exacerbations in patients with chronic obstructive pulmonary disease (COPD). A mix of ...

telemedicine Researchers examined the risks for pneumonia and exacerbation of COPD after PPI treatment for GERD. The risk for symptom exacerbation reduced after PPI treatment for patients with GERD ...

Researchers at Mass General Brigham and Karolinska Institutet have identified a new method to predict asthma exacerbations ...

HBV coinfection with acute exacerbation was associated with significantly worse survival outcomes in pediatric T-ALL.